KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Payables (2016 - 2025)

Exact Sciences (EXAS) has disclosed Payables for 16 consecutive years, with $175.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 48.08% to $175.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $175.9 million, a 48.08% decrease, with the full-year FY2025 number at $175.9 million, down 48.08% from a year prior.
  • Payables was $175.9 million for Q4 2025 at Exact Sciences, up from $129.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $346.7 million in Q3 2024 to a low of $36.0 million in Q1 2021.
  • A 5-year average of $134.5 million and a median of $81.5 million in 2022 define the central range for Payables.
  • Peak YoY movement for Payables: surged 371.32% in 2024, then plummeted 62.69% in 2025.
  • Exact Sciences' Payables stood at $67.8 million in 2021, then increased by 10.45% to $74.9 million in 2022, then grew by 5.21% to $78.8 million in 2023, then soared by 329.77% to $338.7 million in 2024, then crashed by 48.08% to $175.9 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Payables are $175.9 million (Q4 2025), $129.4 million (Q3 2025), and $157.3 million (Q2 2025).